Riya Sharma 
Q4FY26 Revenue stood at ₹30 Cr, registering YoY growth of 13%
Q4FY26 EBITDA at ₹12 Cr, up 40% YoY; EBITDA Margin at 40%
Q4FY26 PAT grew to ₹8 Cr, up 30% YoY
FY26: Revenue at ₹104 Cr, up 48% YoY; EBITDA at ₹38 Cr, up 32% YoY, PAT at ₹24 Cr, up 28% YoY
New Delhi, 1 June, 2026: Gaudium IVF and Women Health Limited, a leading fertility and women’s healthcare platform in India, today announced its Audited Financial Results for the quarter and financial year ended March 31st, 2026.
Consolidated Financial Highlights
(In ₹ Crore)
| Particulars | Q4FY26 | Q4FY25 | YoY | Q3FY26 | QoQ | FY26 | FY25 | YoY |
| Revenue from Operations | 30.35 | 26.92 | 12.74% | 24.50 | 23.85% | 104.35 | 70.72 | 47.56% |
| EBITDA | 12.17 | 8.72 | 39.56% | 6.55 | 85.81% | 37.70 | 28.63 | 31.69% |
| EBITDA Margin % | 40.10% | 32.39% | 771 bps | 26.73% | 1,337 bps | 36.13% | 40.48% | (435) bps |
| Profit After Tax (PAT)* | 8.36 | 6.45 | 29.46% | 3.63 | 130.20% | 24.48 | 19.17 | 27.69% |
| PAT Margin % | 27.54% | 23.98% | 356 bps | 14.81% | 1,273 bps | 23.47% | 27.12% | (365) bps |
*Note: PAT represents Profit After Tax from continuing operations.
Key Financial & Operational Highlights
- Q4 FY26 Revenue from operations stood at ₹30.35 Cr as against ₹26.92 Cr in Q4 FY25, a growth of 12.74% YoY; FY26 Revenue stood at ₹104.35 Cr as against ₹ 70.72 Cr in FY25, a growth of 47.56% YoY — driven by higher patient volume at mature hub and high clinical success rate
- Q4 FY26 EBITDA stood at ₹12.17 Cr as against ₹8.72 Cr, a growth of 39.56% YoY, with EBITDA Margin at 40.10%; FY26 EBITDA stood at ₹37.70 Cr as against ₹ 28.63 Cr in FY25, a growth of 31.69% YoY, with EBITDA Margin at 36.13% supported by operating leverage and a richer mix of advanced IVF protocols
- Q4 FY26 PAT stood at ₹8.36 Cr as against ₹6.45 Cr, an increase of 29.46% YoY, with PAT Margin at 27.54%; FY26 PAT stood at ₹24.48 Cr as against ₹ 19.17 Cr in FY25, an increase of 27.69% YoY, with PAT Margin at 23.47%.
- In April 2026, Gaudium IVF became the first IVF chain in India to formally integrate AI-led embryology into routine clinical practice through a partnership with UK-headquartered IVF 2.0, deploying the SiD (Sperm Identification Device) and ERICA (Embryo Ranking Intelligent Classification Assistant) platforms.
Key Metrics
The Company maintained its network of 7 hubs and 28 spokes in FY26, while delivering a strong clinical pregnancy success rate of 58% on the first IVF attempt
Commenting on the performance, Dr. Manika Khanna, Chairperson and Managing Director, Gaudium IVF and Women Health Limited, said:
“FY26 has been a defining year for Gaudium IVF, the year we transitioned into a listed, institutional and scalable fertility platform. Q4 capped this journey with steady patient volumes across our mature centres and continued discipline on cost, which together translated into the growth you see in revenue, EBITDA and PAT for the quarter and the year.
IVF Treatment remains the engine of the business and will continue to anchor revenue, supported by our 58%-plus clinical success rate in first attempt. The Pharmacy vertical, operated through our subsidiary, is a smaller part of the business and we expect it to remain so. Our 15-bed Hospital facility at Janakpuri rounds off the patient journey from fertility treatment to delivery and post-natal care, a continuum few peers in the listed space offer today.
Looking ahead, our priority is execution. Of the 19 new IVF hubs planned under our IPO use-of-proceeds, 3 hubs are expected to be operational soon, with the balance under Phase I – taking the total to 10 in FY27, to follow, alongside 8 in FY28 and 1 in FY29. This will take us deeper into Tier-II markets while reinforcing existing metro hubs with additional spokes. Alongside physical expansion, we are doubling down on technology: in April we became the first IVF chain in India to adopt AI-led embryology with the SiD and ERICA platforms in partnership with IVF 2.0, and we expect this to meaningfully improve embryo selection consistency, reduce repeat cycles and strengthen patient confidence. With a debt-light balance sheet post-IPO, a clearly funded expansion plan, and an underpenetrated Indian fertility market, we believe Gaudium IVF is well placed to compound growth responsibly over the coming years.”
About Gaudium IVF and Women Health Limited
Founded in 2009, Gaudium IVF and Women Health Limited is a leading fertility and women’s healthcare provider in India, offering advanced reproductive solutions and holistic care to women and couples. With centres across Delhi, Mumbai, Bangalore, Patna, Ludhiana, and Srinagar, Gaudium IVF provides a comprehensive suite of services, including IVF, ICSI, IUI, fertility preservation, infertility treatments, advanced genetic testing, high-risk pregnancy care, and minimally invasive gynecological procedures supported by integrated pregnancy care and 24/7 patient services.
Led by its Chairperson and Managing Director, Dr. Manika Khanna who is an internationally trained infertility specialist, Gaudium IVF combines global expertise with state-of-the-art technology and personalized treatment protocols to deliver trusted clinical outcomes. Committed to ethical, accessible, and patient-centric care, Gaudium IVF also drives impact through the Gaudium Foundation, promoting women’s health, empowerment, and equality.
